Scholar Rock (SRRK) Expected to Announce Quarterly Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK - Get Free Report) is projected to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK traded up $0.05 during trading on Friday, reaching $34.60. The company had a trading volume of 1,093,819 shares, compared to its average volume of 1,162,800. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a 12 month low of $6.76 and a 12 month high of $46.98. The company has a fifty day moving average of $39.68 and a two-hundred day moving average of $31.01. The stock has a market capitalization of $3.28 billion, a P/E ratio of -14.72 and a beta of 0.59.

Insiders Place Their Bets

In related news, insider Jing L. Marantz sold 5,655 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $249,951.00. Following the sale, the insider now owns 67,200 shares in the company, valued at approximately $2,970,240. This trade represents a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mo Qatanani sold 68,510 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the completion of the transaction, the insider now owns 111,084 shares in the company, valued at $4,154,541.60. The trade was a 38.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 292,266 shares of company stock worth $10,996,151. 19.20% of the stock is currently owned by company insiders.

Remove Ads

Analysts Set New Price Targets

Several equities analysts recently commented on SRRK shares. Truist Financial increased their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. Wedbush reaffirmed an "outperform" rating and set a $47.00 price objective on shares of Scholar Rock in a research note on Wednesday, January 29th. Finally, HC Wainwright increased their price target on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $40.43.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.